PMID

Data

Article Title

Organization

Small molecule inhibitors of anthrax lethal factor toxin.

Microbiotix

D-proline-based peptidomimetic inhibitors of anthrax lethal factor.

TBA

Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain.

Panthera Biopharma

Synthesis and biological evaluation of botulinum neurotoxin a protease inhibitors.

Microbiotix

Amiodarone and bepridil inhibit anthrax toxin entry into host cells.

University Of California

Inhibitors of anthrax lethal factor based upon N-oleoyldopamine.

Purdue University

Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.

Microbiotix

Antidotes to anthrax lethal factor intoxication. Part 2: structural modifications leading to improved in vivo efficacy.

Panthera Biopharma

Identifying chelators for metalloprotein inhibitors using a fragment-based approach.

University Of California

Antidotes to anthrax lethal factor intoxication. Part 1: Discovery of potent lethal factor inhibitors with in vivo efficacy.

Panthera Biopharma

In vivo efficacy of beta-cyclodextrin derivatives against anthrax lethal toxin.

National Institute Of Allergy And Infectious Diseases

Synthesis and optimization of thiadiazole derivatives as a novel class of substrate competitive c-Jun N-terminal kinase inhibitors.

Institute For Medical Research

Structure-activity relationship studies of a novel series of anthrax lethal factor inhibitors.

Institute For Medical Research

Inhibitors of anthrax lethal factor.

Purdue University

In silico binding analysis and SAR elucidations of newly designed benzopyrazine analogs as potent inhibitors of thymidine phosphorylase.

Universiti Teknologi Mara (Uitm)

9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore.

Purdue University

Expression of functional mouse 5-HT5A serotonin receptor in the methylotrophic yeast Pichia pastoris: pharmacological characterization and localization.

Max-Planck-Institut

D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs.

Case Western Reserve University

Design and synthesis of novel and potent inhibitors of the type II transmembrane serine protease, matriptase, based upon the sunflower trypsin inhibitor-1.

Georgetown University Medical Center

Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism.

University Of North Carolina At Chapel Hill

Toward an optimal joint recognition of the S1' subsites of endothelin converting enzyme-1 (ECE-1), angiotensin converting enzyme (ACE), and neutral endopeptidase (NEP).

Cnrs

Novel prostaglandin d synthase inhibitors generated by fragment-based drug design.

Astrazeneca

Discovery of a New Class of Potent, Selective, and Orally Bioavailable CRTH2 (DP2) Receptor Antagonists for the Treatment of Allergic Inflammatory Diseases.

Merck Serono

Arginine binding motifs: design and synthesis of galactose-derived arginine tweezers as galectin-3 inhibitors.

Lund University

Thioureido N-acetyllactosamine derivatives as potent galectin-7 and 9N inhibitors.

Lund University

Optimization of a Dihydropyrrolopyrazole Series of Transforming Growth Factor-beta Type I Receptor Kinase Domain Inhibitors: Discovery of an Orally Bioavailable Transforming Growth Factor-beta Receptor Type I Inhibitor as Antitumor Agent.

Eli Lilly